如果将人类抗击癌症的历史视为一场漫长的战役，那么2014年无疑是这场战役中的"诺曼底登陆"。在此之前，尽管手术、放疗、化疗和靶向药 已经构筑了坚固的防线，但面对晚期癌症的肆虐，人类依然显得防守有余而进攻不足。直到PD-1抑制剂的横空出世，战局被彻底改写。 这一年，百时美施贵宝（BMS）的 欧狄沃（Opdivo，俗称O药）与 默沙东（Merck）的 可瑞达（Keytruda，俗称K药）相继问世。它们不直接 毒杀癌细胞，而是通过解除人体免疫系统的"刹车"，唤醒沉睡的免疫T细胞去围剿肿瘤。这一机制的发现，不仅让詹姆斯·艾利森（James Allison）与本庶佑（Tasuku Honjo）在2018年共同登上了诺贝尔奖的领奖台，更在商业世界掀起了一场持续十年的双雄争霸。 从最初O药的独领风骚，到K药的绝地反击，再到如今K药登顶全球"药王"宝座，这段历史充满了科学的偶然、商业的豪赌与宿命般的逆转。 而当我们站在2026年回望，这场战争并未终结，新的挑战者已然在东方崛起。 一、溯源 1. 免疫治疗的"黑暗中世纪" 直到20世纪末，随着T细胞、树突状细胞等免疫大军被逐一识别，科学家们才重新捡起了这把遗落的钥匙。 故事的起 ...

帕博利珠单抗是一种靶向程序性死亡受体-1（PD-1）的人源化单克隆抗体。PD-1 是免疫T细胞表面的一 种关键免疫检查点蛋白，肿瘤细胞可通过激活PD-1通路抑制T细胞的免疫活性，从而实现免疫逃逸。帕 博利珠单抗通过阻断PD-1与其配体PD-L1/PD-L2 的结合，恢复T细胞的肿瘤杀伤功能，增强人体免疫系 统对抗肿瘤的能力。该药物作为免疫检查点抑制剂，已成为多种晚期恶性肿瘤的标准治疗方案之一，革 新了肿瘤治疗格局。 目前国内除原研外，暂未有类似药获批上市。 本次帕博利珠单抗注射液临床试验获批，标志着药物可正式开展对应临床研究，进一步验证安全性与有 效性，为后续注册上市奠定基础，同时丰富公司产品管线，优化产品结构。 格隆汇2月25日丨华兰生物(002007.SZ)公布，2026 年2月25日，华兰生物工程股份有限公司参股公司华 兰安康生物股份有限公司（原名：华兰基因工程有限公司，以下简称"华兰安康"）收到国家药品监督管 理局《药物临床试验批准通知书》（通知书编号：2026LP00498）。 华兰安康研发的帕博利珠单抗注射液为生物类似药。帕博利珠单抗原研产品（商品名：可瑞达®， Keytruda®）由默沙东公司开 ...

格隆汇2月25日｜华兰生物(002007.SZ)公告称，公司参股公司华兰安康收到国家药品监督管理局《药物 临床试验批准通知书》，同意帕博利珠单抗注射液按生物类似药开展临床试验。帕博利珠单抗注射液为 生物类似药，由默沙东公司开发，是全球首个获批上市的PD-1抑制剂之一。目前国内除原研外，暂未 有类似药获批上市。本次临床试验获批，标志着药物可正式开展对应临床研究，进一步验证安全性与有 效性，为后续注册上市奠定基础，同时丰富公司产品管线，优化产品结构。但药品研发具有周期长、环 节多、风险高的特点，后续尚需完成全部临床试验、生产申报、国家药监局审批等环节，各环节结果均 存在不确定性；同时面临临床数据与进度不及预期、市场竞争激烈、行业政策及技术迭代变化等风险。 ...

Core Insights - The global pharmaceutical industry is witnessing a significant shift in the rankings of best-selling drugs, with several products surpassing $10 billion in sales for 2025 [1][2]. Group 1: Sales Performance - Novo Nordisk's semaglutide briefly topped the sales chart in Q1 2025 but was ultimately surpassed by Eli Lilly's tirzepatide, with both drugs exceeding $30 billion in sales [1][3]. - Tirzepatide achieved a remarkable year-on-year sales growth of 121%, while semaglutide's growth was only 13% [3]. - The sales figures for semaglutide in the first half of 2025 reached $16.683 billion, maintaining its position as a top-selling drug [3]. Group 2: Competitive Landscape - The GLP-1 drug class is experiencing intense competition, with both tirzepatide and semaglutide being key players [4][5]. - The market is dominated by Novo Nordisk and Eli Lilly, but Chinese pharmaceutical companies are also making significant strides in this area [5][6]. - New GLP-1 drugs are under development, including Novo Nordisk's CagriSema and Eli Lilly's retatrutide, which shows potential for greater weight loss than tirzepatide [5]. Group 3: Oncology and Autoimmune Drugs - The PD-1 inhibitor pembrolizumab (Keytruda) remains a top seller in oncology, with sales reaching $31.68 billion in 2025, despite falling to third place [7]. - Nivolumab (Opdivo) also crossed the $10 billion mark, achieving sales of $10.29 billion [8]. - In the autoimmune disease sector, drugs like dupilumab and risankizumab achieved sales of $17.8 billion and $17.562 billion, respectively [8]. Group 4: Anticoagulants - The anticoagulant apixaban continues to show strong sales growth, with BMS reporting $14.443 billion in sales, a year-on-year increase of 8% [9]. - Pfizer's reported revenue from apixaban reached $8 billion, making it their second-largest selling product [9].

Group 1 - The core point of the article is that Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Gene Engineering Co., Ltd., received a clinical trial application acceptance notice from the National Medical Products Administration for the domestic production of Pembrolizumab injection [1] - Pembrolizumab is a biosimilar drug developed by the company, targeting multiple cancers including melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1] - The original product of Pembrolizumab, marketed as Keytruda, was developed by Merck and is one of the first PD-1 inhibitors approved globally, recognized for its clinical value across various significant tumor indications [1] Group 2 - Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), which plays a crucial role in immune checkpoint regulation [2] - The drug works by blocking the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring T cell anti-tumor activity and enhancing the immune system's ability to combat tumors [2] - As an immune checkpoint inhibitor, Pembrolizumab has become a standard treatment for various advanced malignancies, revolutionizing the landscape of cancer treatment [2] - Currently, there are no similar drugs approved for marketing in China, aside from the original product [2]

Core Insights - The approval of the combination therapy of Bemarituzumab and Pembrolizumab marks the first and currently only perioperative treatment option for muscle-invasive bladder cancer (MIBC) patients who are not suitable for cisplatin-based chemotherapy, significantly improving survival outcomes compared to standard surgery [1][2] Group 1: Treatment Approval and Efficacy - The FDA has approved the combination of Bemarituzumab (an antibody-drug conjugate targeting Nectin-4) and Pembrolizumab (a PD-1 inhibitor) for neoadjuvant treatment in adult patients with muscle-invasive bladder cancer [1] - The approval is based on the pivotal Phase III EV-303 study, which demonstrated a 60% reduction in the risk of recurrence, progression, or death compared to surgery alone, and a 50% reduction in mortality risk [1][2] - The combination therapy is expected to redefine treatment standards for cisplatin-ineligible MIBC patients, addressing a long-standing unmet medical need [2][3] Group 2: Clinical Study Results - In the EV-303 study, the event-free survival (EFS) rate for the combination therapy group was 74.7%, compared to 39.4% for the surgery-only group, with a median EFS not yet reached for the combination group versus 15.7 months for the surgery group [2] - The overall survival (OS) data indicated a two-year survival probability of 79.7% for the combination group, compared to 63.1% for the surgery group, with a median OS not yet reached for the combination group versus 41.7 months for the surgery group [2] Group 3: Safety Profile - The safety profile of the combination therapy aligns with previous reports, with no new safety signals identified [3] - Common adverse reactions (≥20%) included laboratory abnormalities such as elevated blood glucose and hemoglobin levels, as well as fatigue and rash [3] - The incidence of grade 3 or higher adverse events was 71.3% in the combination therapy group compared to 45.9% in the surgery group [3] Group 4: Ongoing Research - The ongoing Phase III EV-304 study is evaluating the combination of Bemarituzumab and Pembrolizumab in the perioperative setting for cisplatin-eligible MIBC patients [4]

Core Viewpoint - The company Fuhong Hanlin (02696) has seen a significant stock price increase following the announcement that its innovative PD-1 inhibitor, H drug Surulitinib, has been officially included by the NMPA as a breakthrough therapy for gastric cancer treatment [1] Group 1: Company Developments - Fuhong Hanlin's H drug Surulitinib has been recognized as a breakthrough therapy by the NMPA for use in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer [1] - The phase 3 clinical study for the H drug targeting this indication has met its primary endpoint, potentially offering patients improved survival benefits and quality of life [1] Group 2: Market Context - As of the announcement date, there are currently no targeted PD-1 monoclonal antibody drugs approved globally for neoadjuvant/adjuvant treatment of gastric cancer [1] - According to the latest IQVIA MIDAS data, the global sales for targeted PD-1 monoclonal antibody drugs are projected to reach approximately $45.704 billion in 2024 [1]

Group 1 - The core point of the article is that Fuhong Hanlin's innovative PD-1 inhibitor, H drug Surulitinib, has been officially included by the NMPA as a breakthrough therapy for gastric cancer, which could significantly improve patient survival and quality of life [1] - Fuhong Hanlin's stock rose over 6% in the afternoon trading session, with a current price of 66.95 HKD and a trading volume of 63.1355 million HKD [1] - The phase III clinical study for the H drug has met its primary endpoint, indicating its potential to replace postoperative adjuvant chemotherapy in the perioperative treatment of gastric cancer [1] Group 2 - As of the announcement date, there are no approved targeted PD-1 monoclonal antibody drugs for neoadjuvant/adjuvant treatment of gastric cancer globally [1] - According to IQVIA MIDAS data, the global sales of targeted PD-1 monoclonal antibody drugs are projected to reach approximately 45.704 billion USD in 2024 [1]

Core Viewpoint - The completion of patient enrollment in the Phase III clinical trial of BA1104 (Nivolumab injection) by the company marks a significant milestone, as it is the first biosimilar of Opdivo to enter Phase III trials in China [1][2] Group 1: Company Developments - BA1104 is a humanized monoclonal antibody targeting the PD-1 receptor, designed to enhance T-cell anti-tumor responses by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2 [1] - The Phase III trial is a randomized, double-blind, multi-center study comparing the efficacy, safety, and immunogenicity of BA1104 with Opdivo in combination with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma [2] - The results of the completed Phase I trial indicated that BA1104 is highly comparable to Opdivo in terms of pharmacokinetics, safety, and immunogenicity, achieving all study endpoints [2] Group 2: Market Potential - The PD-1 inhibitors, including BA1104, represent a major advancement in cancer immunotherapy, with expanding clinical applications and significant market potential [2] - Opdivo is projected to generate approximately $9.3 billion in global sales in 2024 [2] - The Chinese antibody market based on PD-1/L1 is expected to reach 59.9 billion RMB by 2030, indicating substantial growth opportunities in this sector [2]

Core Viewpoint - The company has completed patient enrollment for the Phase III clinical trial of BA1104 (Nivolumab Injection) in China, making it the first biosimilar of Opdivo to enter Phase III trials domestically [1][2] Company Summary - BA1104 is a humanized monoclonal antibody (IgG4 subtype) targeting the programmed cell death protein 1 (PD-1) receptor, enhancing T-cell anti-tumor responses by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2 [1] - The Phase III trial is a randomized, double-blind, multi-center study comparing the efficacy, safety, and immunogenicity of BA1104 combined with chemotherapy against Opdivo in patients with advanced or metastatic esophageal squamous cell carcinoma [2] - The completed Phase I trial results indicate that BA1104 is highly comparable to Opdivo in terms of pharmacokinetics, safety, and immunogenicity, achieving all study endpoints, with results published in the international journal "BioDrugs" [2] Industry Summary - PD-1 inhibitors represent a major approach in cancer immunotherapy, with ongoing breakthroughs in combination therapies and the synergistic development of diverse immunotherapies expanding their clinical application boundaries [2] - The global sales of Opdivo are projected to reach approximately $9.3 billion in 2024 [2] - According to a Frost & Sullivan report, the market size for PD-1/L1 antibodies in China is expected to reach 59.9 billion RMB by 2030 [2]